The comparative study about the efficacy and safety of alternative DPP-4 (dipeptidyl peptidase-4) inhibitor sitagliptin and the rapid-acting insulin secretagogue (glinide) in patients with type 2 diabetes

The comparative study about the efficacy and safety of alternative DPP-4 (dipeptidyl peptidase-4) inhibitor sitagliptin and the rapid-acting insulin secretagogue (glinide) in patients with type 2 diabetes - SINGLE Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003479

Enrollment

Registered

2010-04-18

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Sitagliptin Mitiglinide or nateglinide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes controlled on a glinide

Exclusion criteria

Exclusion criteria: Patients with moderate to severe renal insufficiency

Design outcomes

Primary

Measure	Time frame
HbA1c, Glycoalbumin, 1,5-AG, plasma glucose	—

Secondary

Measure	Time frame
Serum C-peptide, IRI, IRG, HOMA-B, SUIT index, CPR index, proinsulin/insulin, Body weight	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026